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Abstract
Background Bovine colostrum (COL) has been advocated as a nutritional countermeasure to exercise-induced immune 
dysfunction, but there is a lack of research with clinically relevant in vivo measures.
Aim To investigate the effects of COL supplementation on in vivo immunity following prolonged exercise using experimental 
contact hypersensitivity (CHS) with the novel antigen diphenylcyclopropenone (DPCP).
Methods In a double-blind design, 31 men were randomly assigned to COL (20 g/day) or placebo (PLA) for 58 days. 
Participants ran for 2 h at 60% maximal aerobic capacity on day 28 and received a primary DPCP exposure (sensitisation) 
20 min after. On day 56, participants received a low-dose-series DPCP challenge to elicit recall of in vivo immune-specific 
memory (quantified by skinfold thickness 24 and 48 h later). Analysis of the dose–response curves allowed determination 
of the minimum dose required to elicit a positive response (i.e., sensitivity).
Results There was no difference in summed skinfold thickness responses between COL and PLA at 24 h (p = 0.124) and 
48 h (p = 0.405). However, sensitivity of in vivo immune responsiveness was greater with COL at 24 h (p < 0.001) and 48 h 
(p = 0.023) with doses ~ twofold greater required to elicit a positive response in PLA.
Conclusions COL blunts the prolonged exercise-induced decrease in clinically relevant in vivo immune responsiveness to a 
novel antigen, which may be a mechanism for reduced illness reports observed in the previous studies. These findings also 
suggest that CHS sensitivity is highly relevant to host defence.
Keywords Running · Host defence · Contact hypersensitivity · Diphenylcyclopropenone · Whole integrated immune 
response
Introduction
Upper respiratory tract symptoms (URS) are the most com-
mon ailment reported by athletes to medicine clinics at 
major sporting events [1–3]. It has long been considered that 
transient perturbations in host immunity following strenuous 
training and/or competition increase susceptibility to infec-
tious (pathogenic) causes of URS [4]. Numerous studies 
have shown significant decreases in circulating and mucosal 
immune function in individuals undergoing heavy physical 
exertion [5]. The majority of these studies have relied on 
in vitro measures of immune function where the clinical 
relevance of such investigations is often questioned [6]. The 
importance of in vivo measures of immunity to determine 
the clinical relevance of a change in immune function in 
an exercise context has been recognised [7]. The clinical 
relevance of such measures is further supported in immune-
deficient populations (e.g., HIV-positive children), whereby 
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the degree of responses relates to relevant clinical outcomes 
(respiratory infections and mortality) [8–10].
Topical skin exposure to novel antigens (contact sensitisa-
tion) such as diphenylcyclopropenone (DPCP) allows for the 
effects of systemic stressors on the induction and elicitation 
phases of in vivo T-cell-mediated immune response to be 
quantified by oedema and erythema [11–13]. By use of this 
model of experimental contact sensitisation, Harper-Smith 
et al. [14] demonstrated that participation in a single bout 
of prolonged (2 h) moderate exercise compared to rest sig-
nificantly reduced both the induction and the elicitation of 
in vivo cell-mediated immunity. Recent work demonstrating 
that the same exercise stressor does not impair responses to 
a skin irritant [15] has further established this as a control-
lable, reproducible, and valid marker of exercise-induced 
immunity (antigen T-cell-mediated responses). This rigor-
ous model with control of both the dose and timing of the 
sensitisation to the novel antigen permits the investigation 
of strategies to counter the effects of prolonged exercise on 
immunity.
Several nutritional interventions have been proposed 
as countermeasures to exercise-induced immune dysfunc-
tion. Oral supplementation of bovine colostrum (COL) 
reduces the episode incidence and days of URS in adults 
involved in exercise training by a magnitude that is greater 
than the smallest clinically important difference [16]. The 
mechanism(s) behind such effects remain unclear, but it has 
been proposed that it is linked to COL reducing perturba-
tions in cellular immunity following prolonged exercise 
[17]. We have previously demonstrated that COL blunts the 
decrease in blood neutrophil effector functions following 
prolonged exercise [18, 19]. Shing et al. [20] observed a 
prevention of a post-exercise decrease in cytotoxic/suppres-
sor T cells during an intensive period of training. Although 
such in vitro or ex vivo measures are considered sufficiently 
reliable and sensitive markers of immunity [7], it is difficult 
to conclude with any degree of certainty that modulations 
in these parameters alone are responsible for the alteration 
observed in susceptibility to URS. The cutaneous measures 
of immunity such as contact hypersensitivity (CHS) repre-
sent an integrated and highly coordinated (in vivo) immune 
response to a challenge induced by a novel antigen [21].
To our knowledge, no studies have assessed the effects of 
COL on the in vivo immune response to a novel antigen fol-
lowing prolonged exercise. Therefore, the aim of this study 
was to investigate the effects of COL supplementation on the 
induction of a cell-mediated response to DPCP following 
prolonged exercise. We hypothesised that COL supplemen-
tation would blunt prolonged exercise-induced decreases 
in the induction of in vivo immunity. Although not on the 
World Anti-Doping Agency’s list of banned substances, sup-
plementation of COL is not recommended by the governing 
body, because it contains growth factors such as insulin-like 
growth factor I (IGF-I) that “may influence the outcome of 
anti-doping tests” [22]. Given that this study may have clini-
cally relevant implications for athletes, the secondary aim 
was to investigate whether COL caused any unwarranted 
changes in IGF-I concentrations.
Materials and methods
Trial design
This double-blind randomised placebo controlled trial was 
approved by the Aberystwyth University Research Ethics 
Committee and all experimental procedures were conducted 
in line with the Declaration of Helsinki. All participants pro-
vided both verbal and written consent following information 
on experimental procedures. All laboratory visits involving 
exercise also required completion of a physical activity read-
iness questionnaire (PAR-Q).
Participants
Thirty-four participants were eligible for the present inves-
tigation (Fig. 1). Participants were included if they were 
male, healthy (as determined by PAR-Q), recreationally 
active, non-smokers, and aged 18–45 years. Exclusion cri-
teria were use of regular medication or dietary supplements, 
known allergy or intolerances to milk products, eczema or 
dermatitis on the upper arm or lower back, regular exposure 
to ultraviolet radiation, tendency for abnormal scarring (e.g. 
keloid), previous contact with DPCP, participation in other 
research studies that involved skin patch testing, or blood 
donation or infection 4 weeks prior to the study.
Supplementation
Participants were randomly assigned (using a computerised 
list generated at randomiser.org by a researcher not involved 
in data collection) to a COL group (n = 17) or placebo (PLA) 
group (n = 17) following stratification on age and aerobic fit-
ness (determined in first incremental exercise test). COL and 
PLA powdered supplements were provided in sealed sachets 
that did not identify the contents to a study investigator 
(blinded to group allocation) for distribution to participants. 
Participants consumed 20 g per day (10 g morning and even-
ing: mixed with 250–300 mL of water and consumed on an 
empty stomach) of COL or an isoenergetic/isomacronutrient 
PLA (skimmed milk powder and milk protein concentrate) 
for 58 days (28 days before and after the main exercise trial, 
and the 2 days of elicitation) (Fig. 2).
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Randomised (n=34) 
Allocated to bovine colostrum group (n=17) 
   - Received allocated intervention (n=17)
Lost to follow up (n=2) 
   - Injury and new medication 
   - Overseas travel 
Included in final analysis (n=15) Included in final analysis (n=16)
Lost to follow up (n=1) 
   - New medication 
Allocated to placebo group (n=17) 
   - Received allocated intervention (n=17)
Eligible and enrolled in study (n=34) 
Screened volunteers (n=38) 
Ineligible for study (n=4) 
   - Age > 45 years (n=1) 
   - Asthma medication (n=1) 
   - Immunosuppressive medication (n=2) 
Fig. 1  Schematic diagram of study design
Consent 
Day 
End of Study 
Bovine colostrum or placebo supplementation 
Randomisation 
    14 
Incremental 
exercise test 
     21 
Familiarisation trial 
11:00 1 h run 60%       max  2OV
28 
Main exercise trial 
07:30 Standardised breakfast; 
10:45 Pre-exercise blood sample; 
11:00 2 h run 60%       max; 
13:00 Post-exercise blood sample; 
13:20 Sensitisation patch applied 
(induction of in vivo immunity)  
2OV
 30
13:20 Sensitisation 
patch removed 
   56
13:20 Dose-series  
patch application 
(elicitation of in  
vivo immunity); 
19:20 Patches  
removed  
    57       58
13:20 Skinfold 
measurement 
   0 
    Baseline
10:45 Blood sample; 
Supplement allocated 
 -2 
Incremental 
exercise test; 
Participant 
demographics 
Fig. 2  Flowchart of study participants
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Preliminary visits and standardisation
Participants performed a continuous incremental test 
(1 km h− 1 min− 1) following 3 min at 7 km h− 1 to volitional 
exhaustion on a treadmill with a 1% grade (PPS 55med, 
Woodway GmbH, Weil am Rhein, Germany). Expired gas 
was analysed by an online breath-by-breath gas analysis 
system (Jaeger Oxycon Pro, Hoechberg, Germany). Strong 
verbal encouragement was provided in the later stages of the 
test to encourage maximal effort. Maximal oxygen uptake 
( V̇O
2
 max) was determined as the highest 30 s average dur-
ing the test.
At least 48 h following the incremental test and after an 
overnight fast (from midnight), participants reported to the 
laboratory at 10:30 for a blood sample (Baseline, day 0) 
prior to commencing supplementation. Fourteen days into 
the supplementation period, V̇O
2
 max of participants was 
re-tested. Seven days later, participants performed a famil-
iarisation trial consisting of a 1 h run to habituate with study 
procedures and verify speed equivalent to 60% V̇O
2
 max.
For the 24 h prior to the main experimental trial, par-
ticipants were provided a standardised diet of 60% (energy 
from) carbohydrate: ~ 5.4 g kg− 1 body mass (BM); 25% fat: 
~ 1.0 g kg− 1 BM; 15% protein: ~ 1.3 g kg− 1 BM and water: 
35 mL kg− 1 BM [23]. This diet matched the estimated daily 
energy expenditure requirements for each participant esti-
mated by the equation of Harris and Benedict [24] multi-
plied by a physical activity factor of 1.5 (note: relative rest 
was required on this day). This diet did not include any caf-
feine or alcohol, and participants were also asked to avoid 
any exercise during this period. On the day of the main 
trial, participants were provided a standardised breakfast 
at 07:30 [total energy: 7.5 kcal kg− 1 BM, carbohydrate: 
~ 1 g kg− 1 BM (60%), fat: ~ 0.2 g kg− 1 BM (25%) and pro-
tein: ~ 0.2 g kg− 1 BM (15%)]. They remained in the lab for 
3 h (during which a bolus of water equivalent to 5 mL kg− 1 
BM was provided). To further standardise dietary intake, 
participants were provided with a lunch prior to departure on 
the day of the main exercise trial [total energy: 5 kcal kg− 1 
BM, carbohydrate: ~ 0.6 g kg− 1 BM (50%), fat: ~ 0.2 g kg− 1 
BM (34%), and protein: ~ 0.2 g kg− 1 BM (16%)].
Experimental procedures
Main exercise trial
A resting blood sample (pre-exercise) was collected at 10:45 
before the 2 h run at 60% V̇O
2
 max commenced at 11:00. All 
participants were permitted diluted cordial (four volumes 
of water to 1 volume of sugar-free cordial at 2 mL kg−1 of 
BM) every 15 min during the exercise but not at end of the 
exercise. Expired gas (2 min) was analysed with measure-
ments commencing at 30, 60, and 90 min of exercise (Jaeger 
Oxycon Pro, Hoechberg, Germany). Heart rate (Polar S610, 
Polar Electro Oy, Kempele, Finland) and rating of per-
ceived exertion (RPE: Borg scale [25]) were monitored and 
recorded every 15 min during the protocol. A venous blood 
sample was collected immediately post-exercise (post-exer-
cise). Participants showered (without the use of body washes 
or shower gels) and returned to the laboratory within 20 min 
of exercise completion.
Induction of contact sensitivity
Participants were sensitised at 13:20 using a single patch 
(22.8 µL of 0.125% DPCP in acetone, 30 µg cm− 2 DPCP) 
applied to the mid-lower back in accordance with the 
previous studies [14, 15, 21]. Following application, the 
patch remained in place for exactly 48 h. Participants were 
instructed to avoid alcohol and exercise during this period.
Elicitation of immune memory
Exactly 28  days following the induction of immune-
specific memory (sensitisation), and in accordance with 
the previous studies [14, 15, 21], participants reported 
to the laboratory for a series of DPCP patches (10 µL of 
0.0048%, 1.24 µg cm− 2; 0.0076%, 1.98 µg cm− 2; 0.0122%, 
3.172  µg  cm− 2; 0.01953%, 5.08  µg  cm− 2; 0.03125%, 
8.12 µg cm− 2; and 0%, 100% acetone) to be applied to 
the volar aspect of their right upper arm, at the same time 
(13:20). To minimise anatomical variability, these patches 
were applied in a randomly allocated order (matched 
between groups). All patches were removed after exactly 6 h.
Assessment of cutaneous responses
Participants returned to the laboratory 24 and 48 h following 
the application of patches for cutaneous responses (oedema, 
by skinfold thickness) to be measured, in triplicate, using 
modified skin fold callipers (Baty, West Sussex, UK) in 
accordance with the previous studies [14, 15, 21]. During 
this 48 h period, and the 24 h prior to application of the 
patches, participants were requested to avoid any exercise 
and alcohol. The dose–response curves were used to conduct 
sensitivity analyses to determine the minimum DPCP dose 
required to elicit a (positive) response. Summed increases 
in skinfold thickness were determined by adding values for 
all doses.
Blood sampling
Participants remained seated, performing minimal move-
ment for 10 min prior to each blood sample with the excep-
tion of immediately post-exercise, which was drawn within a 
few min of exercise cessation. Blood samples were collected 
European Journal of Nutrition 
1 3
by venepuncture [21 gauge precision needle (Becton–Dick-
inson, Oxford, UK)] from an antecubital vein into a vacu-
tainer (Becton–Dickinson, Oxford, UK) containing tripotas-
sium ethylene diamine tetraacetic acid  (K3EDTA). A small 
aliquot was taken from the  K3EDTA tube for whole blood 
measures, whilst the remaining sample was centrifuged at 
1500g for 10 min at 4 °C. Ailquots of plasma were stored at 
− 80 °C for later analysis.
Blood analysis
Leukocyte counts (ABX Pentra 60 C+, Horiba Medical, 
Montpellier, France) were determined on  K3EDTA treated 
whole blood. Glucose and lactate were determined on EDTA 
plasma (Biosen C-Line, EKF Diagnostic, London, UK). 
IGF-I concentration was quantified in duplicate pre-treated 
(to release IGF-I from binding proteins) plasma samples at 
baseline and pre-exercise (4 weeks following supplementa-
tion) via a commercially available enzyme-linked immuno-
sorbent assay (R&D Systems, Abingdon, UK).
Statistical analysis
Sample size estimation: It was not possible to use previous 
data to perform power calculations, since there are no other 
studies that have used the present methods to assess in vivo 
immune function with this supplement. However, we have 
undertaken a number of studies on various immune mark-
ers and, on average, have observed a large effect (Cohen’s 
d = 1.25) with the dosage of bovine colostrum used in the 
present study (e.g., [18, 19, 26]). To detect such a magni-
tude of effect in this study, a sample size of n = 15 per group 
(n = 30 in total) is required to provide > 90% power.
Data shown in the text, tables, and figures are presented 
as mean ± standard deviation unless stated otherwise. Sta-
tistical analysis of the dose–response curves was performed 
using Graph Pad Prism version 7 (GraphPad, San Diego, 
USA). Statistical analyses of all blood measures were per-
formed via SPSS (v22.00; SPSS Inc., Chicago, IL, USA). 
If possible, data not normally distributed were normalised 
with log or square root transformation before further analy-
sis; otherwise, non-parametric tests were used. A two-factor 
mixed ANOVA (group × time) was carried out on blood leu-
kocytes, plasma glucose, lactate, and IGF-I. Any significant 
main effects in the ANOVA were further analysed by post 
hoc two-tailed paired or independent t tests with Holm–Bon-
ferroni correction. Independent t tests were used to compare 
HR, oxygen uptake (%V̇O
2
 max, V̇O
2
 ), RPE, and summed 
skinfold thickness (at 48 h). Mann–Whitney U test was used 
to assess summed skinfold thickness responses to DPCP at 
24 h. Statistical significance was accepted at p < 0.05.
Results
Participants
From initially screened and included volunteers, 31 partici-
pants were analysed in this trial (Fig. 1). Follow-up was not 
possible in two participants from COL group due to injury 
(outside of experimental protocol which also required acute 
anti-inflammatory treatment) and overseas travel leading 
to prolonged period where supplement was not consumed. 
One participant from PLA group was excluded following 
a change in circumstances (prescribed medication), mean-
ing that they no longer met the eligibility criteria. Groups 
remained well matched with no significant differences in 
physical characteristics (Table 1).
Physiological responses to exercise
There was no significant difference in absolute (p = 0.979) 
or relative (p = 0.423) trial V̇O
2
 between the COL 
(2646 ± 254 mL min− 1; 61.4 ± 2.3% V̇O
2
 max) and PLA 
groups (2649 ± 329  mL  min− 1; 62.3 ± 3.3% V̇O
2
 max). 
Similar mean HR (COL, 150 ± 14 bpm; PLA, 150 ± 11 bpm; 
p = 0.910) and RPE (COL, 13.0 ± 1.0; PLA, 12.6 ± 1.2; 
p = 0.365) values were observed during the main exercise 
trials. There was no significant time (p = 0.502), group 
(p = 0.319), or interaction effect (p = 0.633) for plasma 
glucose (COL, pre-exercise: 4.5 ± 0.4  mmol  L− 1, post-
exercise: 4.7 ± 0.7; PLA, pre-exercise: 4.4 ± 0.6, post-
exercise: 4.4 ± 0.6). There was a significant time effect for 
plasma lactate (p < 0.001) with a significant increase from 
pre-exercise (p < 0.001) to post-exercise, but there was no 
group (p = 0.804) or interaction effect [p = 0.506 (COL, pre-
exercise: 1.4 ± 0.4 mmol L− 1, post-exercise: 1.9 ± 0.5; PLA, 
pre-exercise: 1.3 ± 0.2, post-exercise: 2.0 ± 0.7)].
Immune cell counts
No significant group or interaction effects were evident for 
total or differential leukocyte counts (Table 2). A main effect 
of time was observed for all leukocytes (Table 2).
Table 1  Participant characteristics
COL PLA p value
Age (years) 23.4 ± 4.7 25.3 ± 5.5 0.307
Body mass (kg) 76.4 ± 9.2 73.7 ± 8.1 0.388
Height (m) 1.81 ± 0.05 1.79 ± 0.07 0.352
V̇O
2
 max (mL min− 1) 4272 ± 410 4152 ± 529 0.489
V̇O
2
 max (mL kg− 1 min− 1) 56.6 ± 8.0 56.4 ± 5.3 0.962
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Plasma IGF‑I
There was a significant time effect for plasma IGF-I 
(p = 0.003), but there was no group (p = 0.649) or interac-
tion effect (p = 0.987) [COL, baseline: 125 ± 23 ng mL− 1, 
pre-exercise (4 weeks): 135 ± 31 ng mL− 1; PLA, baseline: 
131 ± 33 ng mL− 1, pre-exercise: 140 ± 33 ng mL− 1].
Table 2  Immune cell counts 
prior to and following 
prolonged running
*Significant main effect of time (p < 0.001). Post hoc (analysis for time effects): †Significant difference 
compared to Baseline (p < 0.05), ‡Significant difference compared to pre-exercise
Cell count,  109 × L− 1 Baseline Pre-exercise Post-exercise p values
Group
Time
Interaction
Total leukocytes †,‡ 0.601
COL 5.5 ± 1.8 5.7 ± 1.3 11.6 ± 4.3 < 0.001*
PLA 4.8 ± 1.2 5.3 ± 0.9 12.0 ± 5.7 0.399
Neutrophils † †‡ 0.566
COL 3.0 ± 1.7 3.2 ± 1.2 8.5 ± 4.5 < 0.001*
PLA 2.3 ± 0.8 2.9 ± 0.7 8.5 ± 5.2 0.382
Monocytes †,‡ 0.467
COL 0.5 ± 0.2 0.5 ± 0.1 0.9 ± 0.4 < 0.001*
PLA 0.5 ± 0.1 0.5 ± 0.1 0.9 ± 0.4 0.337
Total lymphocytes †,‡ 0.459
COL 1.7 ± 0.4 1.6 ± 0.4 2.2 ± 0.6 0.001*
PLA 1.8 ± 0.5 1.7 ± 0.4 2.4 ± 0.6 0.939
Neutrophil: lymphocyte † †,‡ 0.371
COL 1.9 ± 1.7 2.1 ± 1.0 3.9 ± 1.7 < 0.001*
PLA 1.3 ± 0.4 1.8 ± 0.5 3.6 ± 2.0 0.430
Fig. 3  Summed increase in skinfold thickness at 24 and 48  h in 
response to DPCP challenge 28 days after sensitisation. Asterisk: par-
ticipants of the non-exercising control arms (n = 32) from the previ-
ous studies [14, 15] serve as an additional comparison (i.e., 120 min 
of seated rest prior to sensitisation with DPCP) to demonstrate typi-
cal decreases in summed skinfold responses to DPCP with prolonged 
exercise. Columns indicate mean values for each group. Error bars 
represent 95% confidence intervals
European Journal of Nutrition 
1 3
In vivo immune responses
The summed skinfold response was not significantly differ-
ent between groups at 24 h (COL: 1.84 ± 1.79 mm, PLA: 
1.01 ± 0.92 mm, p = 0.124) or 48 h (COL, 3.61 ± 3.21 mm; 
PLA, 2.83 ± 1.64 mm, p = 0.405) (Fig. 3). Analysis of the 
dose–response curves allowed determination of the mini-
mum DPCP dose required to elicit a positive response 
(i.e., sensitivity) (Fig. 4). The minimum dose required at 
24 h was 0.4 and 0.8 µg cm− 2 for COL and PLA groups, 
respectively (p < 0.001), indicating that a dose of 2.0-fold 
greater was required to elicit a positive response in the PLA 
group. At 48 h, the threshold was 0.4 and 0.7 µg cm− 2 for 
COL and PLA groups, respectively (p = 0.023), indicat-
ing that a dose of 1.8-fold greater was required to elicit a 
positive response in the PLA group. Direct comparisons 
between groups at each dose revealed a greater skinfold 
thickness response in COL compared to PLA for the low-
est DPCP dose at both 24 h (COL: 0.22 ± 0.25 mm, PLA: 
0.06 ± 0.11 mm, p = 0.011) and 48 h (COL: 0.42 ± 0.50 mm, 
PLA: 0.16 ± 0.19 mm, p = 0.048).
Discussion
The aim of this study was to investigate the effects of 
COL supplementation on the induction of in vivo immune 
responses to a novel antigen following prolonged exercise. 
The previous evidence suggests that completion of pro-
longed exercise prior to sensitisation to the novel sensitis-
ing chemical, DPCP, can impair the induction of antigen-
specific memory [14]. This provides a robust method to 
evaluate the effects of purported nutritional countermeasures 
on exercise-induced immune dysfunction in vivo. COL did 
not significantly affect the overall summed skinfold response 
to DPCP, but COL supplementation induced greater sensi-
tivity of antigen-specific memory recalled 4 weeks following 
the initial sensitisation. A greater contact hypersensitivity 
response to the lowest DPCP dose was also evident in the 
COL group, but there was no difference at the higher doses.
The findings of the present study extend our current 
knowledge on the benefits of COL as an immune-enhancing 
supplement in humans. Evidence, to date, suggests that the 
effects of COL may be more apparent in the early recov-
ery period following prolonged exercise [18, 19]. However, 
the immunoprotective effects of COL (within a model of 
exercise-induced immune dysfunction) thus far in humans 
have only been demonstrated with in vitro measures of blood 
neutrophil function. Although investigations on whole blood 
maintains the proximity of leukocytes and the extracellular 
milieu of leukocytes compared to other in vitro measures of 
immune function, the use of in vivo measures is considered 
more clinically relevant [7, 11, 22]. We previously demon-
strated that COL limits the increased salivary bacterial load 
in physically active males during the winter months [26], 
and proposed this to be a relevant marker of in vivo (innate) 
immunity that needed further testing in an exercise immu-
nology context. Here, we have used a controllable, reproduc-
ible, and valid marker of exercise-induced immunity in vivo.
With regard to the overall reactivity to DPCP, we did not 
observe any significant effects of COL. In the one previous 
study investigating a nutritional countermeasure (carbohy-
drate supplementation during exercise) using this experi-
mental model [21], there were no significant effects on either 
Fig. 4  Skinfold responses to the full dose-series DPCP challenge 
28 days after sensitisation. Asterisk: participants of the non-exercis-
ing control arms (n = 32) from the previous studies [14, 15] serve as 
an additional comparison (i.e., 120  min of seated rest prior to sen-
sitisation with DPCP) to demonstrate typical decreases in sensitivity 
of immune-specific memory to DPCP with prolonged exercise. Points 
indicate mean values for each group. Error bars represent 95% confi-
dence intervals. Dagger: significant difference between PLA and COL 
(p < 0.05)
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sensitivity or overall reactivity to DPCP following prolonged 
exercise. The previous studies [14, 15] have consistently 
shown that participation in prolonged exercise prior to pri-
mary sensitisation to DPCP decreases summed responses of 
all challenge sites and increases the minimum dose (thresh-
old) required to elicit a positive response during recall of 
immune-specific memory. As a result of exercise-induced 
impairment in cell-mediated immunity, a three-to-fourfold 
greater (i.e., lower sensitivity), DPCP dose was required to 
evoke a positive response in the exercise group than the non-
exercising control group. Similarly, when compared to the 
resting groups of Harper-Smith et al. [14] and Diment et al. 
[15], the exercise groups in this study demonstrate a reduc-
tion in summed responses (Fig. 3). However, the findings of 
this study demonstrate that COL acts as a nutritional coun-
termeasure to prolonged exercise-induced decrements in the 
sensitivity of clinically relevant in vivo immune responsive-
ness to a novel antigen.
There is unequivocal evidence that a threshold effect 
exists for cutaneous sensitisation [27–29]. Indeed, with 
experimental contact dermatitis, there are threshold doses 
where an allergic state is not clinically elicited despite prior 
sensitisation [30]. In contrast, a major goal of vaccines is 
to sensitise host defences for future exposure to a pathogen 
[31]. Hence, greater immune responses by the host during 
exposure to low doses of such antigens are deemed to be 
beneficial for limiting the spread of the infectious agent. The 
previous findings of no inhibitory effect of prolonged exer-
cise on skinfold responses to the irritant, croton oil, provide 
evidence that in the context of DPCP, responses are depend-
ent on cell-mediated events rather than local inflammatory 
processes [15]. Given that a recent meta-analysis [16] of 
five randomised controlled trials (including one from our 
laboratory) of COL supplementation showed a reduction in 
the incidence of URS during exercise training [26, 32–34], 
it is likely that an increase in recall sensitivity provides a 
mechanistic explanation for reduced URS. It will be useful, 
however, for future studies to monitor URS in the period 
following DPCP sensitisation. It is beyond the scope of the 
findings of this study and the previous evidence to suggest 
that T-cell-mediated responses at lower doses of DPCP are 
of greater biological significance (i.e. risk of URS) than 
summed responses. Our data, however, does at least sug-
gest that the sensitivity of cutaneous recall responses to 
DPCP gives a better indication of clinically relevant immu-
nological changes following nutritional (bovine colostrum) 
interventions.
It must be acknowledged that the present study design 
does not allow us to fully establish whether the potential 
effect of COL on the immune system occurred during the 
induction and/or the elicitation of cell-mediated immune 
responses. Limiting consumption of COL to the 4 weeks 
between induction and elicitation only might have provided 
mechanistic insight regarding this question, but this does 
not reflect the application of COL in the real-world setting. 
Within the field of contact sensitisation, the main factor con-
sidered to determine the extent of elicitation is the strength 
of the induction [30]. In addition, the stronger the degree of 
induction, the lower the dose that sensitised individuals will 
react to upon any recall challenge [12]. Furthermore, the 
evidence that the induction phase of T-cell memory is more 
susceptible to the effects of prolonged exercise than the elici-
tation phase [14] may also point towards the period where 
participants would have benefited most from a nutritional 
countermeasure such as COL. Biswas et al. [35] did demon-
strate that COL can differentially affect in vitro stimulation 
of human peripheral blood mononuclear cells by enhancing 
IFNγ production during weak antigenic stimulation but not 
under conditions of strong antigen stimulation.
Although T-cell infiltration plays a central role in the 
orchestration of CHS responses, this is initiated by the non-
specific ‘sensitivity’ of other local (dendritic, Langherhans) 
cells that respond to perturbations induced by the antigen 
[36]. In addition to the induction phase, recent evidence 
suggests that the recruitment of antigen-primed CD8+ T 
cells in response to elicitation of immune memory may 
also depend on infiltration and chemoattractants released 
by inflammatory cells (e.g. neutrophils) [37, 38]. It was a 
limitation of the present study that we did not measure circu-
lating cytokines or in vitro measures of immunity alongside 
in vivo immunity. These may have provided some insight 
into the mechanisms of action or the effects of COL on sig-
nals that may have triggered the migration and maturation of 
cells involved in the in vivo response and whether possible 
tissue priming effects resulted in enhanced immunosurveil-
lance (and explain the greater responses at lower concentra-
tions of DPCP in the COL group). Future studies should 
also explore the effects of COL supplementation on immune 
parameters prior to both induction and elicitation separately 
to further determine mechanisms. However, it is important 
to note that the primary outcome measure, CHS, represents 
the whole integrated in vivo immune response that is con-
sidered the most clinically relevant measure [7, 11, 22] and 
also that in vitro responses do not necessarily predict in vivo 
responses [15, 21]. CHS measurements recorded prior to the 
24 h time point may also provide useful information on the 
improved sensitivity in future studies. If there were any mod-
ulatory effects of COL on performance or stress responses, 
this could also contribute indirectly to effects on the immune 
responses. However, the present findings of similar leuko-
cyte trafficking, and physiological measures, between groups 
(along with similar findings in the previous studies that also 
found no difference in stress hormone responses, e.g., [18, 
19]), suggest that subjects in this study were exposed to a 
matched exercise-induced stress, supporting the previous 
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evidence that the effects of COL are not due to such indirect 
mechanisms.
This study provides further evidence that COL, as a 
supplementation regimen that induces clinically relevant 
benefits to immune health, does not increase circulating 
concentrations of IGF-I compared to an isoenergetic/iso-
macronutrient placebo. The previous evidence from one 
laboratory had suggested increases in IGF-I following short-
periods (≤ 2 weeks) of COL supplementation [39, 40], but 
one of these studies was unable to confirm that it was orally 
administered IGF-I that appeared in the circulation (i.e., 
IGF-I was not absorbed from COL). An important limita-
tion in these studies was the choice of placebo (dextrose 
only) as the addition of daily protein supplementation has 
been shown to induce similar elevations in IGF-I [41]. Sub-
sequently, changes in circulating IGF-I following COL have 
not been replicated by other investigators including larger 
doses and longer duration of supplementation [42–45], 
which, in one study, was supported by no positive values 
in urine samples analysed within an International Olympic 
Committee-accredited laboratory [45]. Furthermore, in a 
previous study [26], we conducted a comprehensive metabo-
lomics analysis and found no differences that would suggest 
COL could influence the outcome of a doping test. The bal-
ance of evidence, therefore, does not seem to support the 
claim that COL can increase IGF-I or influence doping tests.
Conclusion
In summary, COL did not significantly affect the overall 
reactivity of in vivo response to a novel antigen but did blunt 
the prolonged exercise-induced decrease in sensitivity of the 
immune responsiveness. A difference in response to DPCP 
was evident at the lowest recall dose but not at the higher 
doses. Together with the previous findings (e.g., effects of 
COL on host defence and illness susceptibility), these results 
may also suggest that the sensitivity of CHS responses is 
highly relevant to host defence and in vivo protection against 
infection. The present study was undertaken in a fed state (to 
replicate real-world practices of athletes) with a recreational 
athlete population, and presents the first evidence of a nutri-
tional strategy to counter exercise-induced immunodepres-
sion assessed via an established, clinically relevant in vivo 
marker of immunity.
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